Central America Gastric Cancer Treatment Market, By Type (Adenocarcinoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Lymphoma and Others), Stages (Stage III, Stage II, Stage IV, Stage I and Others), Treatment (Chemotherapy, Targeted Therapy, Immune Checkpoint Inhibitors and Others), Route of Administration (Parenteral, Oral and Others), End User (Hospitals, Specialty Clinics, Research & Academic Institutes and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Industry Trends and Forecast to 2029.
Central America Gastric Cancer Treatment Market Analysis and Insights
Gastric adenocarcinoma is the fourth most common type of cancer and the second leading cause of cancer death in the world. Stomach cancer is an abnormal growth of cells that begins in the stomach. Stomach cancer, also known as gastric cancer, can affect any part of the stomach. In most of the world, stomach cancers form in the main part of the stomach (stomach body). But in the U.S., stomach cancer is more likely to affect the area where the esophagus meets the stomach. This area is called the gastroesophageal junction.
Increase in incidence of gastrointestinal tumors with the growing pace of geriatric population is demonstrating the escalation in the number of gastric cancer treatment. Owning to this, it is estimated that growing geriatric population is a major driving factor for the growth of the market.
The gastric cancer treatment is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that the inherited gastric cancer treatment will grow at a CAGR of 7.2% during the forecast period of 2022 to 2029.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Pricing in USD
|
|
Segments Covered
|
By Type (Adenocarcinoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Lymphoma, and Others), Stages (Stage I, Stage II, Stage III, Stage IV, and Others), Treatment (Chemotherapy, Targeted Therapy, Immune Checkpoint Inhibitors and Others), Route of Administration (Oral, Parenteral and Others), End user (Hospitals, Specialty Clinics, Research & Academic Institutes and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others)
|
|
Countries Covered
|
Costa Rica, Guatemala, Panama, Dominican Republic and Rest of Central America
|
|
Market Players Covered
|
Hoffmann-La Roche Ltd., Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Laboratorio Varifarma SA, Seven pharma, Janssen Global Services, LLC (A subsidiary of Johnson & Johnson Services, Inc.) and Sanofi among others
|
Gastric Cancer Treatment Market Dynamics
Drivers
- Increase in Incidence of Gastrointestinal Tumours, Lymphoma, and Adenocarcinoma
The increased incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma is increasing the demand for the early detection and diagnosis via utilizing the latest technology, thereby propelling the growth of the Central America gastric cancer treatment market.
- Rise in Alcohol Consumption and Surge in Smoking
The combined use of cigarettes and alcohol poses health concerns and severe public health issue that collectively lead to gastric cancer. A chemical chain reaction occurs every time a smoker inhales a lit cigarette, producing dozens of hazardous chemicals. Cigarette smoke contains substances inhaled through the lips, through the tongue and mouth, down the throat, and into the lungs, producing inflammation and exposing that aero-digestive tract to cancer-causing chemicals.
Also, the high incidence of obesity in these countries is expected to drive the growth of Central America gastric cancer treatment market.
Furthermore, Increase in strategic initiatives by key players, advancement in medical technology, recent advancements in gastric cancer treatment, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the gastric cancer treatment market.
Opportunities
- Healthcare Expenditure of Central American Countries
Moreover, the increase in awareness and treatment-seeking rate and emerging reimbursement policies for the treatment will boost new opportunities for the market's growth rate.
Also, the increasing drug approvals will provide beneficial opportunities for the gastric cancer treatment market in the forecast period of 2022-2029. Also, the partnership and agreement by major players will escalate the growth rate of the gastric cancer treatment market in the future.
Restraints/Challenges
However, the costs associated with other medical care and interventions (such as surgical interventions and radiotherapy) and supportive care (such as anti-emetics and hematopoietic growth factors) would make overall care even more unaffordable. Even with insurance coverage, patients living with cancer in many countries have reported financial stress, to the extent that they may lower the treatment dose, partially fill prescriptions, or even forego treatment altogether.
This gastric cancer treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Gastric Cancer treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Gastric cancer disease is the 5th most commonly diagnosed cancer in the world, and the 7th most prevalent. Gastric cancer is more prevalent in males. In developed countries, gastric cancer is 2.2 times more likely to be diagnosed in males than females. In developing countries, this ratio is 1.83. In 5 countries worldwide, gastric cancer has the highest incidence among all cancers for males.
Most cancers of the stomach (about 90% to 95%) are adenocarcinomas. These cancers develop from the gland cells in the innermost lining of the stomach (the mucosa). Stomach cancer mostly affects older people. The average age of people when they are diagnosed is 68. About 6 of every 10 people diagnosed with stomach cancer each year are 65 or older. The lifetime risk of developing stomach cancer is higher in men (about 1 in 96) than in women (about 1 in 152). But each person's risk can be affected by many other factors
The gastric cancer treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Post COVID-19 Impact on Gastric Cancer Treatment Market
The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in anticonvulsant medication adherence during the pandemic.
Recent Development
- In March 2021, Amgen and Five Prime Therapeutics, a clinical-stage biotechnology company that is focused on developing immuno-oncology and targeted cancer therapies, announced an agreement under which Amgen will acquire Five Prime Therapeutics. The acquisition will also include Bemarituzumab, A Phase 3 program for gastric cancer
Central America Gastric Cancer Treatment Market Scope
Central America gastric cancer treatment market is categorized into six notable segments, which are based on type, stage, treatment, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Type
- Adenocarcinoma
- Lymphoma
- Gastrointestinal stromal tumor
- Carcinoid tumor
- Others
On the basis of type, the market is segmented into adenocarcinoma, lymphoma, gastrointestinal stromal tumor, carcinoid tumor, and others.
Stage
- Stage I
- Stage II
- Stage III
- Stage IV
- Others
On the basis of stage, the market is segmented into stage I, stage II, stage III, stage IV, and others.
Treatment
- Chemotherapy
- Targeted Therapy
- Immune Checkpoint Inhibitors
- Others
On the basis of treatment, the market is segmented into chemotherapy, targeted therapy, immunotherapy, and others.
Route of Administration
- Oral
- Parenteral
On the basis of route of administration, the market is segmented into oral and parenteral.
End User
- Hospitals
- Specialty Clinics
- Research and Academic Institutes
- Others
On the basis of end-users, the Central America gastric cancer treatment market is segmented into hospitals, specialty clinics, research and academic institutes and others.
Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Others
Central America gastric cancer treatment market is also segmented on the basis of distribution channel into retail pharmacy, hospital pharmacy and others.
Pipeline Analysis
The pipeline analysis of drugs includes various pipeline therapies such as Zolbetuximab (IMAB362) plus mFOLFOX6, Nivolumab and Ipilimumab, Pembrolizumab (MK-3745) + Cisplatin, Regorafenib (Stivarga, BAY73-4506), lapatinib, NCT03653507, Durvalumab or Placebo and FLOT Chemotherapy. Astellas Pharma Inc., Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., Bayer AG, Novartis AG are involved in the development of potential drugs for the improvement of treatment of gastric cancer.
Gastric Cancer Treatment Market Regional Analysis/Insights
The gastric cancer treatment market is analysed and market size insights and trends are provided by country, type, stages, treatment, route of administration, end-user and distribution channel as referenced above.
The countries covered in the gastric cancer treatment market report are Costa Rica, Guatemala, Panama, Dominican Republic and rest of Central America.
Costa Rica dominates the gastric cancer treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and well-developed healthcare infrastructure in this country.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Central America Gastric Cancer Treatment Market Share Analysis
The gastric cancer treatment market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on gastric cancer treatment.
Some of the major companies operating in the Central America gastric cancer treatment market are F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Laboratorio Varifarma SA, Seven pharma, Janssen Global Services, LLC (A subsidiary of Johnson & Johnson Services, Inc.) and Sanofi, and others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analysed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global Vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
SKU-